The information contained within this announcement is deemed
by the Company to constitute inside information as stipulated under
the UK version of the EU Market Abuse Regulation 596/2014 which is
part of UK law by virtue of the European Union (Withdrawal) Act
2018, as amended and supplemented from time to time. Upon the
publication of this announcement, this inside information is now
considered to be in the public domain.
14
August 2024
IXICO plc
("IXICO" or the
"Company")
Long term contract win for a study
in Huntington's Disease
IXICO plc (AIM: IXI), the precision
analytics company delivering intelligent insights in neuroscience,
is pleased to announce that it has been contracted by a US based
pharma client to provide its imaging biomarker services for a Phase
1/2 clinical trial for patients with Huntington's Disease (HD). The
trial is expected to run for up to ten years and contribute close
to £2m to the Company's order book.
Giulio Cerroni, Chief Executive
Officer of IXICO, commented:
"IXICO's expertise
in providing advanced imaging biomarkers and radiological reads for
HD is widely recognised. We are delighted to be awarded this new
contract and look forward to support our client's efforts in this
important HD development programme."
For
further information please contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets
Limited (Nominated Adviser
and
Sole Broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Nigel Birks/Harriet Ward (Corporate
Broking)
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
|
|
|
|
|
About IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More information is
available on www.IXICO.com and follow us on
Twitter @IXICOnews